SlideShare a Scribd company logo
1 of 1
Download to read offline
Surviving Sepsis Campaign Guidelines for
  Management of Severe Sepsis and Septic Shock
  This is a summary of the Surviving Sepsis Campaign               In patients requiring vasopressors, place an arterial            Prone ARDS patients requiring potentially injurious levels
  Guidelines for Management of Severe Sepsis and Septic            catheter as soon as practical.                                   of FiO2 or plateau pressure. Only prone patients not at
  Shock condensed from Dellinger RP, Carlet JM, Masur H,                                                                            high risk from positional changes.
  et al: Surviving Sepsis Campaign guidelines for management       Consider vasopressin in patients with refractory shock
  of severe sepsis and septic shock. Crit Care Med 2004;           despite adequate fluid resuscitation and high-dose con-          To prevent ventilator-associated pneumonia maintain
  32:858-871. This version does not contain the rationale          ventional vasopressors. Vasopressin is not recommended           mechanically ventilated patients in a semirecumbent
  or appendices contained in the primary publication.              as a replacement for norepinephrine or dopamine as a             position (head of bed raised 45 degrees), unless con-
  Please refer to the guidelines for additional information        first-line agent. Administer vasopressin at infusion rates       traindicated.
  at www.survivingsepsis.org.                                      of 0.01–0.04 units/minute in adults.
                                                                                                                                    Use a weaning protocol and have mechanically ventilated
 ∆ Indicates one of the goals chosen for implementation in         Inotropic Therapy                                                patients undergo a spontaneous breathing trial (SBT), at
 the Institute of Healthcare Improvement's change pack-            Consider dobutamine in patients with low cardiac output          least daily, to evaluate for ventilation discontinuation.
 age, i.e. part of the “sepsis bundle.”                            despite fluid resuscitation. Continue to titrate vasopressor
                                                                   to mean arterial pressure of 65 mm Hg or greater.                SBT options include a low level of pressure support with
                                                                                                                                    continuous positive airway pressure 5 cm H2O or a
  Initial Resuscitation                                            Do not increase cardiac index to achieve an arbitrarily          T-piece. Prior to SBT, patients should: 1) be arousable;
∆ Begin resuscitation immediately in patients with                 predefined elevated level of oxygen delivery.                    2) be hemodynamically stable without vasopressors;
  hypotension or elevated serum lactate. Resuscitation                                                                              3) have no new potentially serious conditions; 4) have low
  goals:                                                            Steroids                                                        ventilatory and end-expiratory pressure requirement; and
      • Central venous pressure: 8–12 mm Hg                       ∆ Treat patients who still require vasopressors despite fluid     5) require FiO2 levels that can be safely delivered with a
      • Mean arterial pressure ≥65 mm Hg                            replacement with hydrocortisone 200–300 mg/day, for             face mask or nasal cannula.
      • Urine output ≥0.5 mL.kg -1.hr -1                            7 days in three or four divided doses or by continuous
      • Central venous or mixed venous oxygen                       infusion.                                                       Consider extubation if SBT is successful.
        saturation ≥70%
                                                                   Optional:                                                        Sedation, Analgesia, and Neuromuscular
∆ If central venous oxygen saturation or mixed venous                 • Perform 250-microgram adrenocorticotropic                   Blockade in Sepsis
  oxygen saturation of 70% is not achieved with a central               hormone (ACTH) stimulation test and discontinue             Use sedation protocols for critically ill mechanically
  venous pressure of 8–12 mm Hg, then transfuse packed                  steroids in patients who are responders (increase           ventilated patients. Measure the sedation goal with a
  red blood cells to achieve a hematocrit of ≥30% and/or                in cortisol of > 9 µg/dL).                                  standardized subjective sedation scale.
  administer a dobutamine infusion of up to a maximum of
  20 µg.kg-1.min-1.                                                    • Decrease steroid dose if septic shock resolves.            Target sedation to predetermined endpoints (sedation
                                                                                                                                    score). Use either intermittent bolus sedation or continu-
  Diagnosis                                                            • Taper corticosteroid dose at end of therapy.               ous infusion sedation with daily interruption/lightening
  Before starting antibiotics obtain two or more blood                                                                              to produce awakening. Retitrate if necessary.
  cultures. At least one blood draw should be percutaneous             • Add fludrocortisone (50µg orally once a day)
  and one should be through each vascular assist device                  to this regimen.                                           Avoid neuromuscular blockers (NMBs), if at all possible.
  that has been in place longer than 48 hours. Obtain                                                                               If NMBs must be utilized for longer than the first 2 to 3
  cultures from other sites as indicated – cerebrospinal fluid,    Do not use corticosteroids >300 mg/day of hydrocorti-            hours of mechanical ventilation, use either intermittent
  respiratory secretions, urine, wounds, and other body fluids.    sone to treat septic shock.                                      bolus as required or continuous infusion with monitoring
                                                                                                                                    of depth of block with train of four monitoring.
  Antibiotic Therapy                                               Do not use corticosteroids to treat sepsis in the absence
∆ Begin intravenous antibiotics within first hour of recog-        of shock unless the patient’s endocrine or corticosteroid         Glucose Control
  nition of severe sepsis.                                         history warrants.                                               ∆ Maintain blood glucose <150 mg/dL (8.3mmol/L)
                                                                                                                                     following initial stabilization. Use continuous insulin
  Administer one or more drugs that are active against likely       Recombinant Human Activated                                      and glucose infusion. Monitor blood glucose every 30 – 60
  bacterial or fungal pathogens. Consider microorganism             Protein C (rhAPC)                                                minutes until stabilized, then monitor every 4 hours.
  susceptibility patterns in the community and hospital.          ∆ rhAPC is recommended in patients at high risk of death
                                                                    (APACHE II(≥25, sepsis-induced multiple organ failure,          Include a nutritional protocol for glycemic control.
  Reassess antimicrobial regimen 48–72 hours after                  septic shock, or sepsis-induced acute respiratory distress
  starting treatment with the objective of using a narrow           syndrome) and with no absolute contraindication related         Renal Replacement
  spectrum antibiotic.                                              to bleeding risk or relative contraindication that outweighs    Intermittent hemodialysis and continuous veno venous
                                                                    the potential benefit of rhAPC.                                 hemofiltration (CVVH) are considered equivalent.
  Consider combination therapy for neutropenic patients                                                                             CVVH offers easier management in hemodynamically
  and those with Pseudomonas infections.                           Blood Product Administration                                     unstable patients.
                                                                   Following resolution of tissue hypoperfusion, and in the
  Stop antimicrobial therapy immediately if the condition          absence of significant coronary artery disease or acute          Bicarbonate Therapy
  is determined to be a noninfectious cause.                       hemorrhage, transfuse red blood cells when hemoglobin            Do not use bicarbonate therapy for the purpose of
                                                                   decreases to <7.0 g/dL (<70 g/L) to target a hemoglobin          improving hemodynamics or reducing vasopressor
  Source Control                                                   of 7.0 – 9.0 g/dL.                                               requirements when treating hypoperfusion induced lactic
∆ Evaluate patient for a focus of infection amenable to                                                                             acidemia with pH ≥7.15.
  source control measures including abscess drainage or            Do not use erythropoietin to treat sepsis-related anemia.
  tissue debridement.                                              Erythropoietin may be used for other accepted reasons.           Deep Vein Thrombosis (DVT) Prophylaxis
                                                                                                                                    Use either low-dose unfractionated heparin or low-mole-
  Choose the source control measure that will cause the            Do not use fresh frozen plasma to correct laboratory             cular weight heparin. Use a mechanical prophylactic
  least physiologic upset and still accomplish the clinical        clotting abnormalities unless there is bleeding or planned       device, such as compression stockings or an intermittent
  goal.                                                            invasive procedures.                                             compression device, when heparin is contraindicated.
                                                                                                                                    Use a combination of pharmacologic and mechanical
  Institute source control measures as soon as an infection        Do not use antithrombin therapy.                                 therapy for patients who are at very high risk for DVT.
  focus in need of source countrol has been identified.
                                                                   Administer platelets when counts are <5000/mm3 (5 X              Stress Ulcer Prophylaxis
  Remove intravascular access devices that are a potential         109/L) regardless of bleeding. Transfuse platelets when          Provide stress ulcer prophylaxis. The preferred agents
  infection source promptly after establishing other vascu-        counts are 5000 to 30,000/mm3 (5–30 X 109/L) and there           are H2 receptor inhibitors.
  lar access.                                                      is significant bleeding risk. Higher platelet counts
                                                                   (≥50,000/mm3 [50 X 109/L]) are required for surgery or           Consideration for Limitation of Support
  Fluid Therapy                                                    invasive procedures.                                             Discuss advance care planning with patients and
  (see initial resuscitation timing recommendations)                                                                                families. Describe likely outcomes and set realistic
                                                                    Mechanical Ventilation of Sepsis-Induced                        expectations.
  Use crystalloids or colloids.                                     Acute Lung Injury (ALI)/ARDS
                                                                  ∆ Avoid high tidal volumes coupled with high plateau
∆ Give fluid challenge to patients with suspected inade-            pressures. Reduce tidal volumes over 1–2 hours to a low         Sponsoring Organizations: American Association of Critical-Care
  quate tissue perfusion at a rate of 500 –1000 mL of               tidal volume (6 ml per kilogram of lean body weight) as         Nurses; American College of Chest Physicians; American
  crystalloids or 300–500 mL of colloids over 30 minutes            a goal in conjunction with the goal of maintaining              College of Emergency Physicians; American Thoracic Society;
  and repeat if blood pressure and urine output do not              end-inspiratory plateau pressures <30 cm H2O.                   Australian and New Zealand Intensive Care Society; European
  increase and there is no evidence of intravascular volume                                                                         Society of Clinical Microbiology and Infectious Diseases;
  overload.                                                        If necessary, minimize plateau pressures and tidal volumes       European Society of Intensive Care Medicine; European
                                                                   by allowing PaCO2 to increase above normal.                      Respiratory Society; Infectious Disease Society of America;
  Vasopressors                                                                                                                      International Sepsis Forum; Society of Critical Care Medicine;
  Start vasopressor therapy when fluid challenge fails to          Set a minimum amount of positive end-expiratory pressure         Surgical Infection Society.
  restore adequate blood pressure and organ perfusion, or          (PEEP) to prevent lung collapse at end expiration.
  transiently until fluid resuscitation restores adequate          Set PEEP based on severity of oxygenation deficit and
  perfusion.                                                       guided by the FiO2 required to maintain adequate oxy-
                                                                   genation (ARDSnet guidelines) or titrate PEEP accord-
  Either norepinephrine or dopamine administered through           ing to bedside measurements of thoracopulmonary com-
  a central catheter is the initial vasopressor of choice.         pliance.
                                                                                                                                    This wall chart distributed by the Society of Critical Care Medicine
  Do not use low-dose dopamine for renal protection.
                                                                                                                                                                                Revised June 2004

More Related Content

What's hot

ESA- antitrombotic therapy
ESA- antitrombotic therapyESA- antitrombotic therapy
ESA- antitrombotic therapyHelga Komen
 
Anesthesia in patients on anti coagulants
Anesthesia in patients on anti coagulantsAnesthesia in patients on anti coagulants
Anesthesia in patients on anti coagulantsNavin Jain‬
 
Journal club 19 08-2015
Journal club 19 08-2015Journal club 19 08-2015
Journal club 19 08-2015Kunal Mahajan
 
Crash cart familiarizaton with Arrythmias
Crash cart familiarizaton with ArrythmiasCrash cart familiarizaton with Arrythmias
Crash cart familiarizaton with Arrythmiasjoanna remollino
 
Anticoagulant and regional anaesthesia
Anticoagulant and regional anaesthesiaAnticoagulant and regional anaesthesia
Anticoagulant and regional anaesthesialogon2kingofkings
 
Perioperative management of antithrombotic therapy
Perioperative management of antithrombotic therapyPerioperative management of antithrombotic therapy
Perioperative management of antithrombotic therapyZaito Hjimae
 
Anaesthesia for patient with anticoagulant
Anaesthesia for patient with anticoagulantAnaesthesia for patient with anticoagulant
Anaesthesia for patient with anticoagulantAnaestHSNZ
 
Presentation 22ndmay
Presentation 22ndmayPresentation 22ndmay
Presentation 22ndmayNavin Jain‬
 
Perioperative anticoagulant management
Perioperative anticoagulant managementPerioperative anticoagulant management
Perioperative anticoagulant managementjim kuok
 
Tenecteplase X Alteplase no Acidente Vascular Cerebral - AVC
Tenecteplase  X Alteplase no Acidente Vascular Cerebral - AVCTenecteplase  X Alteplase no Acidente Vascular Cerebral - AVC
Tenecteplase X Alteplase no Acidente Vascular Cerebral - AVCJeferson Espindola
 
Landmark Critical Care Clinical Trials
Landmark Critical Care Clinical TrialsLandmark Critical Care Clinical Trials
Landmark Critical Care Clinical TrialsSherif Elbadrawy
 
Warfarin Bridging
Warfarin BridgingWarfarin Bridging
Warfarin BridgingJenny Chan
 
Gp IIa IIIb inhibitor- kiran sotang
Gp IIa IIIb inhibitor- kiran sotangGp IIa IIIb inhibitor- kiran sotang
Gp IIa IIIb inhibitor- kiran sotangKiran Sotang
 
Natriuretic peptide in chf and acs,VIRBHAN
Natriuretic peptide in chf and acs,VIRBHANNatriuretic peptide in chf and acs,VIRBHAN
Natriuretic peptide in chf and acs,VIRBHANDr Virbhan Balai
 
Rivaroxaban
RivaroxabanRivaroxaban
Rivaroxabantgraphos
 

What's hot (20)

Anticoagulants
AnticoagulantsAnticoagulants
Anticoagulants
 
ESA- antitrombotic therapy
ESA- antitrombotic therapyESA- antitrombotic therapy
ESA- antitrombotic therapy
 
Anesthesia in patients on anti coagulants
Anesthesia in patients on anti coagulantsAnesthesia in patients on anti coagulants
Anesthesia in patients on anti coagulants
 
Journal club 19 08-2015
Journal club 19 08-2015Journal club 19 08-2015
Journal club 19 08-2015
 
Sepsis dr samra
Sepsis dr samraSepsis dr samra
Sepsis dr samra
 
Crash cart familiarizaton with Arrythmias
Crash cart familiarizaton with ArrythmiasCrash cart familiarizaton with Arrythmias
Crash cart familiarizaton with Arrythmias
 
Anticoagulant and regional anaesthesia
Anticoagulant and regional anaesthesiaAnticoagulant and regional anaesthesia
Anticoagulant and regional anaesthesia
 
Perioperative management of antithrombotic therapy
Perioperative management of antithrombotic therapyPerioperative management of antithrombotic therapy
Perioperative management of antithrombotic therapy
 
Rivaroxaban
RivaroxabanRivaroxaban
Rivaroxaban
 
Anaesthesia for patient with anticoagulant
Anaesthesia for patient with anticoagulantAnaesthesia for patient with anticoagulant
Anaesthesia for patient with anticoagulant
 
Presentation 22ndmay
Presentation 22ndmayPresentation 22ndmay
Presentation 22ndmay
 
Perioperative anticoagulant management
Perioperative anticoagulant managementPerioperative anticoagulant management
Perioperative anticoagulant management
 
Tenecteplase X Alteplase no Acidente Vascular Cerebral - AVC
Tenecteplase  X Alteplase no Acidente Vascular Cerebral - AVCTenecteplase  X Alteplase no Acidente Vascular Cerebral - AVC
Tenecteplase X Alteplase no Acidente Vascular Cerebral - AVC
 
Landmark Critical Care Clinical Trials
Landmark Critical Care Clinical TrialsLandmark Critical Care Clinical Trials
Landmark Critical Care Clinical Trials
 
Warfarin Bridging
Warfarin BridgingWarfarin Bridging
Warfarin Bridging
 
Gp IIa IIIb inhibitor- kiran sotang
Gp IIa IIIb inhibitor- kiran sotangGp IIa IIIb inhibitor- kiran sotang
Gp IIa IIIb inhibitor- kiran sotang
 
Bridge trial
Bridge trialBridge trial
Bridge trial
 
NOACs in the ED
NOACs in the EDNOACs in the ED
NOACs in the ED
 
Natriuretic peptide in chf and acs,VIRBHAN
Natriuretic peptide in chf and acs,VIRBHANNatriuretic peptide in chf and acs,VIRBHAN
Natriuretic peptide in chf and acs,VIRBHAN
 
Rivaroxaban
RivaroxabanRivaroxaban
Rivaroxaban
 

Viewers also liked

New microsoft word document
New microsoft word documentNew microsoft word document
New microsoft word documentkhandelwalm
 
SNCRC Abstract FINAL
SNCRC Abstract FINALSNCRC Abstract FINAL
SNCRC Abstract FINALKenya Joseph
 
Die wachsende Bedeutung von Twitter als Kommunikations- und Distributionskana...
Die wachsende Bedeutung von Twitter als Kommunikations- und Distributionskana...Die wachsende Bedeutung von Twitter als Kommunikations- und Distributionskana...
Die wachsende Bedeutung von Twitter als Kommunikations- und Distributionskana...Sven Albrecht
 
ePortfolios an der Technischen Universität Hamburg-Harburg
ePortfolios an der Technischen Universität Hamburg-HarburgePortfolios an der Technischen Universität Hamburg-Harburg
ePortfolios an der Technischen Universität Hamburg-HarburgCPeters2011
 
Schwarz jonas
Schwarz jonasSchwarz jonas
Schwarz jonasrob61jfg
 
Wer zuletzt lacht, Teil 1
Wer zuletzt lacht, Teil 1Wer zuletzt lacht, Teil 1
Wer zuletzt lacht, Teil 1mxgiosi
 
Presentacion en power point
Presentacion en power pointPresentacion en power point
Presentacion en power pointfvalarezo03
 
Carmen Queiroz - Mar do maranhao
Carmen Queiroz - Mar do maranhaoCarmen Queiroz - Mar do maranhao
Carmen Queiroz - Mar do maranhaoCarmen Queiroz
 
La matemàtica
La matemàticaLa matemàtica
La matemàticaximecaivi
 
Guia de-atención-temprana.el-niño-y-la-niña-de-o-a-3-años
Guia de-atención-temprana.el-niño-y-la-niña-de-o-a-3-añosGuia de-atención-temprana.el-niño-y-la-niña-de-o-a-3-años
Guia de-atención-temprana.el-niño-y-la-niña-de-o-a-3-añossusy consuelor ricaldi yauri
 
Rhodes, marios b2
Rhodes, marios b2Rhodes, marios b2
Rhodes, marios b2mxgiosi
 
FLORES EXOTICAS
FLORES EXOTICASFLORES EXOTICAS
FLORES EXOTICASmmunoz8
 
La meva primera presentació web en el power
La meva primera presentació web en el powerLa meva primera presentació web en el power
La meva primera presentació web en el powerlfeliu1
 

Viewers also liked (20)

New microsoft word document
New microsoft word documentNew microsoft word document
New microsoft word document
 
SNCRC Abstract FINAL
SNCRC Abstract FINALSNCRC Abstract FINAL
SNCRC Abstract FINAL
 
Die wachsende Bedeutung von Twitter als Kommunikations- und Distributionskana...
Die wachsende Bedeutung von Twitter als Kommunikations- und Distributionskana...Die wachsende Bedeutung von Twitter als Kommunikations- und Distributionskana...
Die wachsende Bedeutung von Twitter als Kommunikations- und Distributionskana...
 
ePortfolios an der Technischen Universität Hamburg-Harburg
ePortfolios an der Technischen Universität Hamburg-HarburgePortfolios an der Technischen Universität Hamburg-Harburg
ePortfolios an der Technischen Universität Hamburg-Harburg
 
Paco meets Remy
Paco meets RemyPaco meets Remy
Paco meets Remy
 
Schwarz jonas
Schwarz jonasSchwarz jonas
Schwarz jonas
 
Wer zuletzt lacht, Teil 1
Wer zuletzt lacht, Teil 1Wer zuletzt lacht, Teil 1
Wer zuletzt lacht, Teil 1
 
Seniors vs junior
Seniors vs juniorSeniors vs junior
Seniors vs junior
 
9
99
9
 
Jack welch
Jack welchJack welch
Jack welch
 
Same day loans
Same day loansSame day loans
Same day loans
 
Presentacion en power point
Presentacion en power pointPresentacion en power point
Presentacion en power point
 
Carmen Queiroz - Mar do maranhao
Carmen Queiroz - Mar do maranhaoCarmen Queiroz - Mar do maranhao
Carmen Queiroz - Mar do maranhao
 
La matemàtica
La matemàticaLa matemàtica
La matemàtica
 
Pont d'iéna
Pont d'iénaPont d'iéna
Pont d'iéna
 
Guia de-atención-temprana.el-niño-y-la-niña-de-o-a-3-años
Guia de-atención-temprana.el-niño-y-la-niña-de-o-a-3-añosGuia de-atención-temprana.el-niño-y-la-niña-de-o-a-3-años
Guia de-atención-temprana.el-niño-y-la-niña-de-o-a-3-años
 
Rhodes, marios b2
Rhodes, marios b2Rhodes, marios b2
Rhodes, marios b2
 
FLORES EXOTICAS
FLORES EXOTICASFLORES EXOTICAS
FLORES EXOTICAS
 
La meva primera presentació web en el power
La meva primera presentació web en el powerLa meva primera presentació web en el power
La meva primera presentació web en el power
 
Spanish
SpanishSpanish
Spanish
 

Similar to Guidelines poster septic shock

Surviving sepsis Guidelines 2012
Surviving sepsis Guidelines 2012Surviving sepsis Guidelines 2012
Surviving sepsis Guidelines 2012Sourabh Pathak
 
Septic shock management
Septic shock managementSeptic shock management
Septic shock managementdrnabina
 
Approach to Management of Fever & Sepsis (2) copy.pptx
Approach to Management of Fever & Sepsis (2) copy.pptxApproach to Management of Fever & Sepsis (2) copy.pptx
Approach to Management of Fever & Sepsis (2) copy.pptxHarryArwin1
 
Surviving Sepsis Guidelines 2016
Surviving Sepsis Guidelines 2016Surviving Sepsis Guidelines 2016
Surviving Sepsis Guidelines 2016Sun Yai-Cheng
 
Management of sepsis
Management of sepsis Management of sepsis
Management of sepsis Ankur Gupta
 
Surviving sepsis recommendations (1)
Surviving sepsis recommendations (1)Surviving sepsis recommendations (1)
Surviving sepsis recommendations (1)Hossam atef
 
Traumatic brain injury
Traumatic brain injuryTraumatic brain injury
Traumatic brain injuryHossam atef
 
IV%20FLUIDS.pptx
IV%20FLUIDS.pptxIV%20FLUIDS.pptx
IV%20FLUIDS.pptxArunHM3
 
ICU_vasopressors. infographic presenatation by one page
ICU_vasopressors. infographic presenatation by one pageICU_vasopressors. infographic presenatation by one page
ICU_vasopressors. infographic presenatation by one pageDr.Rakesh Reddy
 
Room a b01. mcgee-new sepsis_(en)
Room a b01. mcgee-new sepsis_(en)Room a b01. mcgee-new sepsis_(en)
Room a b01. mcgee-new sepsis_(en)SoM
 
Blood products , transfusion complications
Blood products , transfusion complicationsBlood products , transfusion complications
Blood products , transfusion complicationsIbrahimAlbujays
 

Similar to Guidelines poster septic shock (20)

Surviving sepsis Guidelines 2012
Surviving sepsis Guidelines 2012Surviving sepsis Guidelines 2012
Surviving sepsis Guidelines 2012
 
What is new in sepsis
What is new in sepsisWhat is new in sepsis
What is new in sepsis
 
Bundle of sepsis
Bundle of sepsisBundle of sepsis
Bundle of sepsis
 
Sepsis and septic shock
Sepsis and septic shockSepsis and septic shock
Sepsis and septic shock
 
Septic shock management
Septic shock managementSeptic shock management
Septic shock management
 
Approach to Management of Fever & Sepsis (2) copy.pptx
Approach to Management of Fever & Sepsis (2) copy.pptxApproach to Management of Fever & Sepsis (2) copy.pptx
Approach to Management of Fever & Sepsis (2) copy.pptx
 
Sepsis Treatment
Sepsis TreatmentSepsis Treatment
Sepsis Treatment
 
CME: Management of Severe Sepsis & Septic Shock
CME: Management of Severe Sepsis & Septic ShockCME: Management of Severe Sepsis & Septic Shock
CME: Management of Severe Sepsis & Septic Shock
 
Acute Coronary Syndrome
Acute Coronary SyndromeAcute Coronary Syndrome
Acute Coronary Syndrome
 
Surviving Sepsis Guidelines 2016
Surviving Sepsis Guidelines 2016Surviving Sepsis Guidelines 2016
Surviving Sepsis Guidelines 2016
 
Management of sepsis
Management of sepsis Management of sepsis
Management of sepsis
 
Septic shock copy
Septic shock   copySeptic shock   copy
Septic shock copy
 
Surviving sepsis recommendations (1)
Surviving sepsis recommendations (1)Surviving sepsis recommendations (1)
Surviving sepsis recommendations (1)
 
Traumatic brain injury
Traumatic brain injuryTraumatic brain injury
Traumatic brain injury
 
IV%20FLUIDS.pptx
IV%20FLUIDS.pptxIV%20FLUIDS.pptx
IV%20FLUIDS.pptx
 
sepsis.pptcme.ppt
sepsis.pptcme.pptsepsis.pptcme.ppt
sepsis.pptcme.ppt
 
ICU_vasopressors. infographic presenatation by one page
ICU_vasopressors. infographic presenatation by one pageICU_vasopressors. infographic presenatation by one page
ICU_vasopressors. infographic presenatation by one page
 
sepsis.pptx
sepsis.pptxsepsis.pptx
sepsis.pptx
 
Room a b01. mcgee-new sepsis_(en)
Room a b01. mcgee-new sepsis_(en)Room a b01. mcgee-new sepsis_(en)
Room a b01. mcgee-new sepsis_(en)
 
Blood products , transfusion complications
Blood products , transfusion complicationsBlood products , transfusion complications
Blood products , transfusion complications
 

More from Loveis1able Khumpuangdee (20)

Rollup01
Rollup01Rollup01
Rollup01
 
Protec
ProtecProtec
Protec
 
Factsheet hfm
Factsheet hfmFactsheet hfm
Factsheet hfm
 
Factsheet
FactsheetFactsheet
Factsheet
 
Eidnotebook54
Eidnotebook54Eidnotebook54
Eidnotebook54
 
Data l3 148
Data l3 148Data l3 148
Data l3 148
 
Data l3 147
Data l3 147Data l3 147
Data l3 147
 
Data l3 127
Data l3 127Data l3 127
Data l3 127
 
Data l3 126
Data l3 126Data l3 126
Data l3 126
 
Data l3 113
Data l3 113Data l3 113
Data l3 113
 
Data l3 112
Data l3 112Data l3 112
Data l3 112
 
Data l3 92
Data l3 92Data l3 92
Data l3 92
 
Data l3 89
Data l3 89Data l3 89
Data l3 89
 
Data l2 80
Data l2 80Data l2 80
Data l2 80
 
Hfm reccomment10072555
Hfm reccomment10072555Hfm reccomment10072555
Hfm reccomment10072555
 
Hfm work2550
Hfm work2550Hfm work2550
Hfm work2550
 
Factsheet hfm
Factsheet hfmFactsheet hfm
Factsheet hfm
 
Publichealth
PublichealthPublichealth
Publichealth
 
แนวทางการดาเน ํ นงานป ิ องก ้ นควบค ั มการระบาดของโรคม ุ ือ เท้า ปาก สําหรบแพ...
แนวทางการดาเน ํ นงานป ิ องก ้ นควบค ั มการระบาดของโรคม ุ ือ เท้า ปาก สําหรบแพ...แนวทางการดาเน ํ นงานป ิ องก ้ นควบค ั มการระบาดของโรคม ุ ือ เท้า ปาก สําหรบแพ...
แนวทางการดาเน ํ นงานป ิ องก ้ นควบค ั มการระบาดของโรคม ุ ือ เท้า ปาก สําหรบแพ...
 
hand foot mouth
hand foot mouthhand foot mouth
hand foot mouth
 

Recently uploaded

ACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdfACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdfSpandanaRallapalli
 
AmericanHighSchoolsprezentacijaoskolama.
AmericanHighSchoolsprezentacijaoskolama.AmericanHighSchoolsprezentacijaoskolama.
AmericanHighSchoolsprezentacijaoskolama.arsicmarija21
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Educationpboyjonauth
 
Planning a health career 4th Quarter.pptx
Planning a health career 4th Quarter.pptxPlanning a health career 4th Quarter.pptx
Planning a health career 4th Quarter.pptxLigayaBacuel1
 
Atmosphere science 7 quarter 4 .........
Atmosphere science 7 quarter 4 .........Atmosphere science 7 quarter 4 .........
Atmosphere science 7 quarter 4 .........LeaCamillePacle
 
Grade 9 Q4-MELC1-Active and Passive Voice.pptx
Grade 9 Q4-MELC1-Active and Passive Voice.pptxGrade 9 Q4-MELC1-Active and Passive Voice.pptx
Grade 9 Q4-MELC1-Active and Passive Voice.pptxChelloAnnAsuncion2
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceSamikshaHamane
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxiammrhaywood
 
Full Stack Web Development Course for Beginners
Full Stack Web Development Course  for BeginnersFull Stack Web Development Course  for Beginners
Full Stack Web Development Course for BeginnersSabitha Banu
 
Romantic Opera MUSIC FOR GRADE NINE pptx
Romantic Opera MUSIC FOR GRADE NINE pptxRomantic Opera MUSIC FOR GRADE NINE pptx
Romantic Opera MUSIC FOR GRADE NINE pptxsqpmdrvczh
 
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxMULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxAnupkumar Sharma
 
DATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersDATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersSabitha Banu
 
Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Celine George
 
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTiammrhaywood
 
How to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPHow to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPCeline George
 
Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Celine George
 
ROOT CAUSE ANALYSIS PowerPoint Presentation
ROOT CAUSE ANALYSIS PowerPoint PresentationROOT CAUSE ANALYSIS PowerPoint Presentation
ROOT CAUSE ANALYSIS PowerPoint PresentationAadityaSharma884161
 

Recently uploaded (20)

ACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdfACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdf
 
OS-operating systems- ch04 (Threads) ...
OS-operating systems- ch04 (Threads) ...OS-operating systems- ch04 (Threads) ...
OS-operating systems- ch04 (Threads) ...
 
AmericanHighSchoolsprezentacijaoskolama.
AmericanHighSchoolsprezentacijaoskolama.AmericanHighSchoolsprezentacijaoskolama.
AmericanHighSchoolsprezentacijaoskolama.
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Education
 
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdfTataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
 
Raw materials used in Herbal Cosmetics.pptx
Raw materials used in Herbal Cosmetics.pptxRaw materials used in Herbal Cosmetics.pptx
Raw materials used in Herbal Cosmetics.pptx
 
Planning a health career 4th Quarter.pptx
Planning a health career 4th Quarter.pptxPlanning a health career 4th Quarter.pptx
Planning a health career 4th Quarter.pptx
 
Atmosphere science 7 quarter 4 .........
Atmosphere science 7 quarter 4 .........Atmosphere science 7 quarter 4 .........
Atmosphere science 7 quarter 4 .........
 
Grade 9 Q4-MELC1-Active and Passive Voice.pptx
Grade 9 Q4-MELC1-Active and Passive Voice.pptxGrade 9 Q4-MELC1-Active and Passive Voice.pptx
Grade 9 Q4-MELC1-Active and Passive Voice.pptx
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in Pharmacovigilance
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
 
Full Stack Web Development Course for Beginners
Full Stack Web Development Course  for BeginnersFull Stack Web Development Course  for Beginners
Full Stack Web Development Course for Beginners
 
Romantic Opera MUSIC FOR GRADE NINE pptx
Romantic Opera MUSIC FOR GRADE NINE pptxRomantic Opera MUSIC FOR GRADE NINE pptx
Romantic Opera MUSIC FOR GRADE NINE pptx
 
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxMULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
 
DATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersDATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginners
 
Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17
 
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
 
How to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPHow to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERP
 
Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17
 
ROOT CAUSE ANALYSIS PowerPoint Presentation
ROOT CAUSE ANALYSIS PowerPoint PresentationROOT CAUSE ANALYSIS PowerPoint Presentation
ROOT CAUSE ANALYSIS PowerPoint Presentation
 

Guidelines poster septic shock

  • 1. Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis and Septic Shock This is a summary of the Surviving Sepsis Campaign In patients requiring vasopressors, place an arterial Prone ARDS patients requiring potentially injurious levels Guidelines for Management of Severe Sepsis and Septic catheter as soon as practical. of FiO2 or plateau pressure. Only prone patients not at Shock condensed from Dellinger RP, Carlet JM, Masur H, high risk from positional changes. et al: Surviving Sepsis Campaign guidelines for management Consider vasopressin in patients with refractory shock of severe sepsis and septic shock. Crit Care Med 2004; despite adequate fluid resuscitation and high-dose con- To prevent ventilator-associated pneumonia maintain 32:858-871. This version does not contain the rationale ventional vasopressors. Vasopressin is not recommended mechanically ventilated patients in a semirecumbent or appendices contained in the primary publication. as a replacement for norepinephrine or dopamine as a position (head of bed raised 45 degrees), unless con- Please refer to the guidelines for additional information first-line agent. Administer vasopressin at infusion rates traindicated. at www.survivingsepsis.org. of 0.01–0.04 units/minute in adults. Use a weaning protocol and have mechanically ventilated ∆ Indicates one of the goals chosen for implementation in Inotropic Therapy patients undergo a spontaneous breathing trial (SBT), at the Institute of Healthcare Improvement's change pack- Consider dobutamine in patients with low cardiac output least daily, to evaluate for ventilation discontinuation. age, i.e. part of the “sepsis bundle.” despite fluid resuscitation. Continue to titrate vasopressor to mean arterial pressure of 65 mm Hg or greater. SBT options include a low level of pressure support with continuous positive airway pressure 5 cm H2O or a Initial Resuscitation Do not increase cardiac index to achieve an arbitrarily T-piece. Prior to SBT, patients should: 1) be arousable; ∆ Begin resuscitation immediately in patients with predefined elevated level of oxygen delivery. 2) be hemodynamically stable without vasopressors; hypotension or elevated serum lactate. Resuscitation 3) have no new potentially serious conditions; 4) have low goals: Steroids ventilatory and end-expiratory pressure requirement; and • Central venous pressure: 8–12 mm Hg ∆ Treat patients who still require vasopressors despite fluid 5) require FiO2 levels that can be safely delivered with a • Mean arterial pressure ≥65 mm Hg replacement with hydrocortisone 200–300 mg/day, for face mask or nasal cannula. • Urine output ≥0.5 mL.kg -1.hr -1 7 days in three or four divided doses or by continuous • Central venous or mixed venous oxygen infusion. Consider extubation if SBT is successful. saturation ≥70% Optional: Sedation, Analgesia, and Neuromuscular ∆ If central venous oxygen saturation or mixed venous • Perform 250-microgram adrenocorticotropic Blockade in Sepsis oxygen saturation of 70% is not achieved with a central hormone (ACTH) stimulation test and discontinue Use sedation protocols for critically ill mechanically venous pressure of 8–12 mm Hg, then transfuse packed steroids in patients who are responders (increase ventilated patients. Measure the sedation goal with a red blood cells to achieve a hematocrit of ≥30% and/or in cortisol of > 9 µg/dL). standardized subjective sedation scale. administer a dobutamine infusion of up to a maximum of 20 µg.kg-1.min-1. • Decrease steroid dose if septic shock resolves. Target sedation to predetermined endpoints (sedation score). Use either intermittent bolus sedation or continu- Diagnosis • Taper corticosteroid dose at end of therapy. ous infusion sedation with daily interruption/lightening Before starting antibiotics obtain two or more blood to produce awakening. Retitrate if necessary. cultures. At least one blood draw should be percutaneous • Add fludrocortisone (50µg orally once a day) and one should be through each vascular assist device to this regimen. Avoid neuromuscular blockers (NMBs), if at all possible. that has been in place longer than 48 hours. Obtain If NMBs must be utilized for longer than the first 2 to 3 cultures from other sites as indicated – cerebrospinal fluid, Do not use corticosteroids >300 mg/day of hydrocorti- hours of mechanical ventilation, use either intermittent respiratory secretions, urine, wounds, and other body fluids. sone to treat septic shock. bolus as required or continuous infusion with monitoring of depth of block with train of four monitoring. Antibiotic Therapy Do not use corticosteroids to treat sepsis in the absence ∆ Begin intravenous antibiotics within first hour of recog- of shock unless the patient’s endocrine or corticosteroid Glucose Control nition of severe sepsis. history warrants. ∆ Maintain blood glucose <150 mg/dL (8.3mmol/L) following initial stabilization. Use continuous insulin Administer one or more drugs that are active against likely Recombinant Human Activated and glucose infusion. Monitor blood glucose every 30 – 60 bacterial or fungal pathogens. Consider microorganism Protein C (rhAPC) minutes until stabilized, then monitor every 4 hours. susceptibility patterns in the community and hospital. ∆ rhAPC is recommended in patients at high risk of death (APACHE II(≥25, sepsis-induced multiple organ failure, Include a nutritional protocol for glycemic control. Reassess antimicrobial regimen 48–72 hours after septic shock, or sepsis-induced acute respiratory distress starting treatment with the objective of using a narrow syndrome) and with no absolute contraindication related Renal Replacement spectrum antibiotic. to bleeding risk or relative contraindication that outweighs Intermittent hemodialysis and continuous veno venous the potential benefit of rhAPC. hemofiltration (CVVH) are considered equivalent. Consider combination therapy for neutropenic patients CVVH offers easier management in hemodynamically and those with Pseudomonas infections. Blood Product Administration unstable patients. Following resolution of tissue hypoperfusion, and in the Stop antimicrobial therapy immediately if the condition absence of significant coronary artery disease or acute Bicarbonate Therapy is determined to be a noninfectious cause. hemorrhage, transfuse red blood cells when hemoglobin Do not use bicarbonate therapy for the purpose of decreases to <7.0 g/dL (<70 g/L) to target a hemoglobin improving hemodynamics or reducing vasopressor Source Control of 7.0 – 9.0 g/dL. requirements when treating hypoperfusion induced lactic ∆ Evaluate patient for a focus of infection amenable to acidemia with pH ≥7.15. source control measures including abscess drainage or Do not use erythropoietin to treat sepsis-related anemia. tissue debridement. Erythropoietin may be used for other accepted reasons. Deep Vein Thrombosis (DVT) Prophylaxis Use either low-dose unfractionated heparin or low-mole- Choose the source control measure that will cause the Do not use fresh frozen plasma to correct laboratory cular weight heparin. Use a mechanical prophylactic least physiologic upset and still accomplish the clinical clotting abnormalities unless there is bleeding or planned device, such as compression stockings or an intermittent goal. invasive procedures. compression device, when heparin is contraindicated. Use a combination of pharmacologic and mechanical Institute source control measures as soon as an infection Do not use antithrombin therapy. therapy for patients who are at very high risk for DVT. focus in need of source countrol has been identified. Administer platelets when counts are <5000/mm3 (5 X Stress Ulcer Prophylaxis Remove intravascular access devices that are a potential 109/L) regardless of bleeding. Transfuse platelets when Provide stress ulcer prophylaxis. The preferred agents infection source promptly after establishing other vascu- counts are 5000 to 30,000/mm3 (5–30 X 109/L) and there are H2 receptor inhibitors. lar access. is significant bleeding risk. Higher platelet counts (≥50,000/mm3 [50 X 109/L]) are required for surgery or Consideration for Limitation of Support Fluid Therapy invasive procedures. Discuss advance care planning with patients and (see initial resuscitation timing recommendations) families. Describe likely outcomes and set realistic Mechanical Ventilation of Sepsis-Induced expectations. Use crystalloids or colloids. Acute Lung Injury (ALI)/ARDS ∆ Avoid high tidal volumes coupled with high plateau ∆ Give fluid challenge to patients with suspected inade- pressures. Reduce tidal volumes over 1–2 hours to a low Sponsoring Organizations: American Association of Critical-Care quate tissue perfusion at a rate of 500 –1000 mL of tidal volume (6 ml per kilogram of lean body weight) as Nurses; American College of Chest Physicians; American crystalloids or 300–500 mL of colloids over 30 minutes a goal in conjunction with the goal of maintaining College of Emergency Physicians; American Thoracic Society; and repeat if blood pressure and urine output do not end-inspiratory plateau pressures <30 cm H2O. Australian and New Zealand Intensive Care Society; European increase and there is no evidence of intravascular volume Society of Clinical Microbiology and Infectious Diseases; overload. If necessary, minimize plateau pressures and tidal volumes European Society of Intensive Care Medicine; European by allowing PaCO2 to increase above normal. Respiratory Society; Infectious Disease Society of America; Vasopressors International Sepsis Forum; Society of Critical Care Medicine; Start vasopressor therapy when fluid challenge fails to Set a minimum amount of positive end-expiratory pressure Surgical Infection Society. restore adequate blood pressure and organ perfusion, or (PEEP) to prevent lung collapse at end expiration. transiently until fluid resuscitation restores adequate Set PEEP based on severity of oxygenation deficit and perfusion. guided by the FiO2 required to maintain adequate oxy- genation (ARDSnet guidelines) or titrate PEEP accord- Either norepinephrine or dopamine administered through ing to bedside measurements of thoracopulmonary com- a central catheter is the initial vasopressor of choice. pliance. This wall chart distributed by the Society of Critical Care Medicine Do not use low-dose dopamine for renal protection. Revised June 2004